caa a22 4500 445335416 CHVBK 20180317142753.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1245/s10434-011-1703-6 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1703-6 Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution [Elektronische Daten] [Philippe Metellus, Isabelle Nanni-Metellus, Christine Delfino, Carole Colin, Aurelie Tchogandjian, Bema Coulibaly, Frederic Fina, Anderson Loundou, Marylin Barrie, Olivier Chinot, L'Houcine Ouafik, Dominique Figarella-Branger] Background: Cancer stem cells are thought to represent the population of tumorigenic cells responsible for tumor development. The CD133 antigen has been described as a putative stem cell marker in malignant brain tumor that could identify such a tumorigenic population in a subset of glioblastoma. To date, the correlation between CD133 expression in primary glioblastoma and patient prognosis is not clearly established. To address this question we investigated the relationship between CD133 mRNA expression and patient outcome in a glioblastoma patient cohort. Materials and Methods: The quantitative expression of CD133 stem cell antigen mRNA using real-time QRT-PCR was assessed in a cohort of 48 consecutive primary glioblastoma patients treated by chemoradiation with temozolomide. Results: On multivariate survival analysis, high CD133 mRNA expression was a significant (P=0.007) prognostic factor for adverse progression-free and overall survival independent of extent of resection (P=0.012) and MGMT methylation status (P=0.002). Patient age was also an independent prognosticator of overall survival (P=0.037). Furthermore, according to the conjoined expression of CD133 mRNA and MGMT status, the patients were categorized into 3 groups with homogenous prognosis. Conclusions: These findings constitute conclusive evidence that the measurement of the mRNA expression of CD133 stem cell antigen actually impacts the survival of GBM patients. Society of Surgical Oncology, 2011 Metellus Philippe Service de Neurochirurgie, Hôpital de la Timone, Marseille, France aut Nanni-Metellus Isabelle Laboratoire de Transfert d'Oncologie Biologique, AP-HM, Marseille, France aut Delfino Christine Université de la Méditerranée Aix-Marseille, Marseille, France aut Colin Carole Université de la Méditerranée Aix-Marseille, Marseille, France aut Tchogandjian Aurelie Université de la Méditerranée Aix-Marseille, Marseille, France aut Coulibaly Bema Université de la Méditerranée Aix-Marseille, Marseille, France aut Fina Frederic Laboratoire de Transfert d'Oncologie Biologique, AP-HM, Marseille, France aut Loundou Anderson Université de la Méditerranée Aix-Marseille, Marseille, France aut Barrie Marylin Unité de Neurooncologie, Hopital de la Timone, Marseille, France aut Chinot Olivier Université de la Méditerranée Aix-Marseille, Marseille, France aut Ouafik L'Houcine Université de la Méditerranée Aix-Marseille, Marseille, France aut Figarella-Branger Dominique Université de la Méditerranée Aix-Marseille, Marseille, France aut Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2937-2945 1068-9265 18:10<2937 2011 18 10434 https://doi.org/10.1245/s10434-011-1703-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1703-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Metellus Philippe Service de Neurochirurgie, Hôpital de la Timone, Marseille, France aut NATIONALLICENCE 700 1- Nanni-Metellus Isabelle Laboratoire de Transfert d'Oncologie Biologique, AP-HM, Marseille, France aut NATIONALLICENCE 700 1- Delfino Christine Université de la Méditerranée Aix-Marseille, Marseille, France aut NATIONALLICENCE 700 1- Colin Carole Université de la Méditerranée Aix-Marseille, Marseille, France aut NATIONALLICENCE 700 1- Tchogandjian Aurelie Université de la Méditerranée Aix-Marseille, Marseille, France aut NATIONALLICENCE 700 1- Coulibaly Bema Université de la Méditerranée Aix-Marseille, Marseille, France aut NATIONALLICENCE 700 1- Fina Frederic Laboratoire de Transfert d'Oncologie Biologique, AP-HM, Marseille, France aut NATIONALLICENCE 700 1- Loundou Anderson Université de la Méditerranée Aix-Marseille, Marseille, France aut NATIONALLICENCE 700 1- Barrie Marylin Unité de Neurooncologie, Hopital de la Timone, Marseille, France aut NATIONALLICENCE 700 1- Chinot Olivier Université de la Méditerranée Aix-Marseille, Marseille, France aut NATIONALLICENCE 700 1- Ouafik L'Houcine Université de la Méditerranée Aix-Marseille, Marseille, France aut NATIONALLICENCE 700 1- Figarella-Branger Dominique Université de la Méditerranée Aix-Marseille, Marseille, France aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2937-2945 1068-9265 18:10<2937 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer